STALE?Report written 7 days ago · at $2.93entry levels may be stale — re-check before acting

ASPI

ค่าขนมSMALL CAP

ASP Isotopes Inc. · NASDAQ · Materials / Nuclear Fuel & Specialty Isotopes

$2.93

▼ 0.85%

MCap $448M

ใกล้ 52-week low ($2.90–$14.49 range) หลังร่วงจาก high เกือบ -80% ระหว่างรอ catalyst ที่กำลังจะถึง

BusinessNuclear/Quantum Materials · Aerodynamic Separation Process + Quantum Enrichment tech — enriching Silicon-28, Ytterbium-176, Carbon-14 + HALEU nuclear fuel; first-ever commercial isotope shipments targeted Q3 2026

Thesis

ASP Isotopes (ASPI) is a speculative nuclear/quantum-materials play racing toward its first-ever commercial isotope shipments — Silicon-28 (quantum computing / advanced semiconductors) targeted by the close of Q3 2026, with Ytterbium-176 (Lutetium-177 cancer-radiotherapy feedstock) following in H2 2026. Three US Si-28 supply contracts are already signed and the Pretoria enrichment facility was restarted in May 2026 (stock popped +24% same day on the restart news alone) after a 7-month rebuild from an Oct 2025 equipment failure — meaning this exact catalyst has already slipped once and could slip again. Cash of $219.6M (Jun 30, 2026) against ~$16M/month total cash burn gives an estimated ~13-14 months of runway (30+ months on pure operating burn alone) — clean by the survival-check bar, but an active ~$106M resale shelf plus an ESOP-related shelf keeps dilution a live, ordinary risk, not a survival flag. Position for 2-5% of portfolio only — this is a binary, pre-revenue-scale bet on a company that has already missed one delivery date.

📝 Primary Verdict · Core Holding

SPECULATIVEค่าขนม

Entry rule (backlog #40): turbo lane's medianPctAtAnchor is -13.7% (n=19, 78.9% negative) — Entry 1 at report price is NOT preferred; wait for the Entry 2 dip zone. Stops sit wider than the turbo lane's -24.1% median MAE. Size 2-5% max — this is a binary pre-shipment bet on a name that already missed one delivery date.

81

score / 100 ⓘ

⚡ Catalyst

⚛️ Silicon-28 first commercial shipmentIMMINENT

First-ever commercial shipments of enriched Si-28 for quantum computing / advanced semiconductor customers. 3 US contracts already signed; company restarted the first 18 stages of its upgraded Pretoria facility in May 2026 after a 7-month rebuild and reaffirmed a Q3 2026 shipment target.

~Sep 30, 2026 (Q3 target)

🧬 Ytterbium-176 first commercial shipmentH2 2026

Feedstock for Lutetium-177 cancer-radiotherapy drugs. Company shipped a first Yb-176 sample to a prospective customer in Aug 2025; targeting initial commercial shipments in H2 2026, behind Si-28 in the queue.

H2 2026

💰 ~$9M highly-enriched isotope supply contractONGOING

Existing supply agreement with a US customer for a highly enriched isotope — early proof of real commercial offtake ahead of the full-scale isotope ramp.

Ongoing

🎯 Entry Point

Entry 1

$2.93

Current price — pre-Q3-shipment, thesis unconfirmedNow

Entry 2PREFERRED

$2.4–2.6

Turbo entry-rule dip zone — historical median move from report price to just after catalyst is -13.7% (n=19, 78.9% negative)ถ้าย่อก่อน catalyst

Entry 3

$1.85

Deep dip — near thesis-still-intact support, above hard-stop territoryถ้าร่วงหนักแต่ thesis ยังไม่พัง

✅ Take Profit

TP1

Base — Si-28/Yb-176 shipments confirmed + early revenue ramp visible (through ~Q4 2026 earnings)

$4.25

+45.1%

TP2

Bull — multi-isotope revenue ramp, EBITDA path toward 2031 guide gets credible

$7.33

+150.2%

TP3 🌙

Moon — full commercial scale across all 3 isotope lines, quantum-computing Si-28 demand inflects, near current analyst consensus

$13.19

+350.2%

🔴 Stop Loss

Tight Stop

Deliberately wider than the turbo lane's -24.1% median MAE bar — a breach here means the Q3 shipment timeline is credibly cracking

$2.05

-30%

Hard Stop

Risk-of-zero territory — 2nd consecutive shipment delay + dilution scenario, thesis broken

$1.32

-55%

Risk / Reward

Tight stop (-30%) vs TP2 Bull (+150.2%)

5 : 1

⚠ Asymmetric ✅ — clears the turbo 5:1 target

📅 Estimate Date

Si-28 first commercial shipment

3 US contracts signed; 2nd attempt after the Oct 2025 delay

By Sep 30, 2026

Target: within days of this report

Q3 2026 earnings / business update

First hard read on whether Si-28/Yb-176 shipments actually converted to booked revenue

Nov 2026 (est.)

est. revenue ramp confirmation

📈 Possible Up % — Scenario Spread

Bear

-55%

$1.32

Base

+45%

$4.25

Bull

+150%

$7.33

Moon

+350%

$13.19

← downsideupside →

🏛️ Fed / Macro Risk — MEDIUM

Assesses how Fed policy / interest rates / inflation affect this stock — LOW = minimal risk, HIGH = proceed with caution

Rate Outlook

Fed still holding a restrictive-but-easing bias through late 2026; funding costs for pre-revenue small caps remain elevated versus the 2020-21 zero-rate era.

Inflation

Inflation running near-target lowers the odds of a hawkish surprise, but doesn't remove the capital-markets sensitivity of a company that just filed a $106M resale shelf.

Sector Impact

Nuclear/critical-materials names have kept a policy-driven risk premium (AI power demand, US isotope supply-chain onshoring) that has partly decoupled them from the standard rate-sensitivity playbook — but ASPI is small/illiquid enough that a broad risk-off move in speculative small caps would hit it disproportionately regardless of the Fed's stance on nuclear policy specifically.

Summary

MEDIUM Fed risk: rate policy itself is a secondary driver here versus company-specific execution risk (does Si-28 actually ship in Q3), but a broad risk-off macro tape would compound an already-binary, dilution-exposed setup.

🎯 Analyst Targets

Wall Street price targets vs the current price — cross-check our TP levels

Consensus (3 analysts, Strong Buy)

Strong Buy$13+344%

WallStreetZen 1Y model

Buy$11+275%

current price $2.93

🔍 Similar-Catalyst Comparable Check

Stocks that went through similar catalyst events — calibrate whether the +30%+ target is realistic

LEU✅ GoodNov 2023

+704%

in 540 days

First commercial HALEU delivery to US DOE, completing Phase 1 of its enrichment contract

Centrus's market cap grew from ~$684M to ~$5.5B over the ~18 months following its first HALEU delivery — the closest real analog to ASPI's Si-28 situation (small-cap proving out a novel domestic enrichment process for the first time), though the move mixed the delivery proof-point with separate DOE/policy tailwinds, so it's a multi-quarter re-rating case, not a single-day pop.

ASPI✅ GoodMay 2026

+24%

in 1 day

Restart of Silicon-28 enrichment facility + Q3 2026 shipment timeline reaffirmed (precursor news, not the shipment itself)

Same company, same catalyst chain, one step earlier — shows the market already reacts sharply to any credible Si-28 proof point. The actual first shipment (this report's catalyst) is a stronger, more concrete milestone than a facility restart, so the reaction could be larger — or could disappoint if volumes/pricing undersell expectations.

⚡ Optional Layer · Tactical Overlay

🎯 Catalyst Spot Mode

Short-term play around the catalyst (Sep 2026 earnings) only — an optional overlay, not a verdict that ranks equal to the Core Holding.

⚠️

Use this stop-loss set (-30% / -20%) only when trading the earnings spot — not for the core holding (use the -30% / -55% set above). If you are holding long-term, follow the core set.

📈Pre-Catalyst Run-up Pattern

+15% to +25%1-4 สัปดาห์ก่อน event

Nuclear-fuel-cycle / isotope names tend to pre-run on ANY positive proof point ahead of the actual shipment — not just the shipment itself. ASPI's own May 2026 facility-restart news (still a precursor, not the shipment) triggered an immediate one-day pop.

🎲Historical Post-Catalyst Move

✅ Catalyst Winavg +40%

range: +24% (single-day precursor pop, ASPI) to +700%+ (multi-quarter re-rating, LEU)· May 2026 (ASPI) / Nov 2023 (LEU)

n=1 for this exact catalystType in skill-feedback (Tier 1, context only) — do not treat as a reliable average. ASPI's own May 2026 restart news popped +24% same day; Centrus (LEU) re-rated from ~$684M to ~$5.5B market cap over the ~18 months following its Nov 2023 first HALEU delivery, though that move mixed the delivery proof-point with separate DOE policy tailwinds.

❌ Catalyst Missavg -24%

range: -18% to -35%· Oct 2025 (ASPI delay disclosure)

No clean single-stock precedent for a FAILED first-shipment on ASPI itself; using the turbo lane's overall medianMAE (-24.1%, skill-feedback.json) as the directional anchor since delivery_beat's own n=1 sample can't support a standalone estimate. ASPI already sold off hard on the Oct 2025 equipment-failure delay disclosure, though the exact single-day % was not independently re-verified this run.

💼Spot Position Sizing

How the recommended % is derived

3%

of portfolio

ค่าขนม position เท่านั้น — delivery_beat catalystType มี n=1 ในข้อมูล historical (Tier 1, context only, ห้ามใช้ inflate/deflate conviction) ต้องอิง turbo lane โดยรวมแทน: hitRate 4.9% (2/41), softHitRate 22%, medianExcessVsBenchPct +2pp, beatBenchRate 56.1%, medianMAE -24.1% (regime note: 5/41 windows มี SPY ลงเกิน 2%) — lane โดยรวมยังพิสูจน์ตัวเองไม่เต็มที่ บวกกับ ASPI เคย delay มาแล้วครั้งนึง (Oct 2025) → 3% ของ portfolio พอ

🛑Stop Loss · Spot Trade

Spot cut-loss levels — separate from the core holding

Before Catalyst

-30%($2.05)

เท่ากับ tight stop — กว้างกว่า turbo lane medianMAE -24.1% ตามเกณฑ์ขั้นต่ำ, หลุดแปลว่า thesis (Si-28 shipment เกิดขึ้นจริงใน Q3 2026) กำลังพัง

After Catalyst (Bad Result)-20%

ถ้า Q3 2026 ปิดไปโดยไม่มี shipment จริง (delay รอบที่ 2) ให้ขายทันที ไม่ต้องรอ hard stop เพราะ credibility ของ management ต่อ timeline จะเสียไปแล้ว

📎 Sources

https://www.tradingview.com/symbols/NASDAQ-ASPI/https://ir.aspisotopes.com/news-events/press-releases/detail/107/asp-isotopes-implements-engineering-enhancements-to https://www.stocktitan.net/news/ASPI/asp-isotopes-implements-engineering-enhancements-to-silicon-28-xgdj5sasx1bz.html https://www.sec.gov/Archives/edgar/data/0001921865/000119312526352603/aspi-20260630.htm https://www.wallstreetzen.com/stocks/us/nasdaq/aspi/stock-forecast https://www.benzinga.com/trading-ideas/movers/26/05/52776943/asp-isotopes-stock-surges-after-silicon-28-facility-restart https://investors.centrusenergy.com/news-releases/news-release-details/centrus-makes-first-haleu-delivery-us-department-energy https://www.fool.com/investing/2026/09/24/is-centrus-energy-the-ultimate-picks-and-shovels/https://finance.yahoo.com/news/lutetium-177-lu-177-market-151600646.html https://www.datainsightsmarket.com/reports/silicon-28-1060380 https://www.engineeringnews.co.za/article/asp-isotopes-expects-first-shipments-of-nuclear-medicine-electronics-isotopes-in-2026-2026-04-13

Generated 2026-09-29 · Not financial advice